Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Diagnosis
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Diagnosis

1 evidence topic · 3 sources

International Delphi consensus on imlifidase desensitization

“crossmatch conversion from positive to negative in patients treated with imlifidase should be confirmed before transplantation” (opens the source at this quote in a new tab)